Details of the Drug Reposition

General Information of This Drug (ID: DMTMCPZ)

Drug Name
KB001A   DMTMCPZ
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Infectious disease DISEM33Q 1A00-CA43.1 Phase 2 [1]
Cystic fibrosis DIS2OK1Q CA25 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01695343) Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00638365) Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa. U.S. National Institutes of Health.